Company · IONS
Ionis Pharmaceuticals
Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
3
3 still marketed
Novel approvals
3
Approvals since 2021
4
Originals and new uses
Phase 3 trials
26
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
- Zanvastro approved NovelPriority reviewOrphanSep 3, 2026
- Tryngolza (Autoinjector) new use Breakthrough therapyPriority reviewOrphanJun 24, 2026
- Dawnzera (Autoinjector) approved NovelOrphanAug 21, 2025
- Tryngolza (Autoinjector) approved NovelBreakthrough therapyPriority reviewOrphanDec 19, 2024
Drugs in development (7)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
- obudanersenION582Phase 33 trials
Ionis Pharmaceuticals · Angelman Syndrome
- SapablursenISIS 702843, ONO-0530Phase 32 trials
Ono Pharmaceutical Co., Ltd. · Polycythemia Vera, Phlebotomy Dependent Polycythemia Vera
- ION363Phase 31 trial
Ionis Pharmaceuticals · Amyotrophic Lateral Sclerosis
- ION337Phase 21 trial
Ionis Pharmaceuticals · Dravet Syndrome
- ION440Phase 21 trial
Ionis Pharmaceuticals · Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome
- ION717Phase 21 trial
Ionis Pharmaceuticals · Prion Disease
- ION775Phase 21 trial
Ionis Pharmaceuticals · Hypertriglyceridemia, Severe Hypertriglyceridemia
Recruiting Phase 3 trials
Largest first.
- CHAMPION: A Study to Evaluate the Efficacy and Safety of Obudanersen (ION582) in Children and Adults With Angelman Syndrome (AS)Pivotal-lookingRecruiting
Ionis Pharmaceuticals, Inc.Ionis Pharmaceuticals (IONS)
NCT07782827 · 30 participants (planned) · Start Sep 30, 2026 · Primary completion May 2028
Drug: obudanersen · For: Angelman Syndrome
Sites: Carrboro, North Carolina
- Donidalorsen Treatment in Children With Hereditary AngioedemaPivotal-lookingRecruiting
Ionis Pharmaceuticals, Inc.Ionis Pharmaceuticals (IONS)
NCT07298447 · 20 participants (planned) · Start Apr 21, 2026 · Primary completion Jun 2029
Drug: Donidalorsen · For: Hereditary Angioedema (HAE)
Sites: Santa Monica, California; Miami, Florida; Baton Rouge, Louisiana · 18 sites in all
- A Study of Olezarsen for the Treatment of Familial Chylomicronemia Syndrome (FCS) in Pediatric ParticipantsPivotal-lookingRecruiting
Ionis Pharmaceuticals, Inc.Ionis Pharmaceuticals (IONS)
NCT07727538 · 12 participants (planned) · Start Jul 31, 2026 · Primary completion Aug 2030
Drug: Olezarsen · For: Familial Chylomicronemia Syndrome
Sites: Birmingham, Alabama; San Francisco, California; Kansas City, Missouri · 6 sites in all
Marketed drugs (3)
Newest FDA action first.
- Zanvastro Zilganersen Sodium · 2026
- Tryngolza (Autoinjector) Olezarsen Sodium · 2024
- Dawnzera (Autoinjector) Donidalorsen Sodium · 2025
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.